Neuronetics, Inc.
$1.1M 2,122 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Lumenis BE inc
Lumenis BE inc reported $1,106,600.16 across General Payments, Research, and Ownership to 694 physicians and teaching hospitals across 694 transactions.
- $1.1M Above-median payer
- All-tracks total
- 694 Above-median volume
- Transactions
- 694 Above-median reach
- Recipients
- −$25.0K
- General Payments vs PY2023
Lumenis BE inc reported $1,106,600.16 across all CMS Open Payments tracks (General + Research + Ownership) to 694 physicians and teaching hospitals in Program Year 2024 - ranking #598 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,106,600.16, averaging $1.6K per recipient.
Lumenis BE inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
20/100
Transaction volume
F
15/100
Physician reach
F
15/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer lumenis-be-inc Lumenis BE inc
$1.1M · #598/1,925 · 0.0% industry · PY2024
- TOT $1.1M
- RANK #598
- SHARE 0.0%
- TXN 694
- RCP 694
- CAT 2
- GEN $1.1M
- ΔGEN −$25.0K
- TOP1 8.0%
- PY 2024
Volume peers
Nearest volume peer: Neuronetics, Inc. ($1.1M)
Lumenis BE inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Lumenis BE inc's CMS-reported General Payments decreased by $25.0K (−2.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: LUMENIS BE INCPY2023: LUMENIS BE INCPY2024: Lumenis BE inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,131,581.29
- PY2024
- $1,106,600.16
What the Data Shows for Lumenis BE inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Lumenis BE inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $1.0M, accounting for 90.6% of this company's General Payments and 666 transactions.
General Payment Breakdown by Type
"Food and Beverage" leads Lumenis BE inc's 2-category general-payment breakdown at $1.0M, 90.6% of the reported total.
How Lumenis BE inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.0M | 666 | 90.6% |
| Compensation for Services Other Than Consulting | $103.5K | 28 | 9.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $253,798.98 (22.9%) of $1,106,600.16 in this company's General Payments records across 432 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Lumenis BE inc
The five named recipients with the highest reported General Payments from this company
- 1
Nathan Lighthizer
$88,000.00 across 4 reported transactions
- 2
Shauna Diggs
$54,897.27 across 11 reported transactions
- 3
Ryan Gustus
$40,075.26 across 4 reported transactions
- 4
James Chelnis
$37,826.45 across 12 reported transactions
- 5
Richard Adler
$33,000.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Lumenis BE inc ranks #598 of 1,925 by total payments (top 31% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,572 of 1,838 by HHI (bottom 15% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Patterson Companies, Inc. : $1.7M total payments, HHI 194
- Amneal Pharmaceuticals LLC : $1.9M total payments, HHI 194
- Rock Medical Orthopedics, Inc. : $23.5K total payments, HHI 194
- ShockWave Medical, Inc : $6.8M total payments, HHI 193
- Almirall LLC : $396.1K total payments, HHI 189
- Neuropace, Inc. : $477.4K total payments, HHI 189
- Lumenis BE inc (this company) : $1.1M total payments, HHI 187
- Leica Microsystems Inc. : $215.9K total payments, HHI 183
- Cosette Pharmaceuticals Inc. : $1.1K total payments, HHI 183
- NeurAxis, Inc. : $12.9K total payments, HHI 182
- Mozarc Medical US LLC : $40.9K total payments, HHI 182
- Smoky Mountain Surgical Llc : $42.8K total payments, HHI 181
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Lumenis BE inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Lumenis BE inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Lumenis BE inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Kyowa Kirin Co., Ltd
$1.1M 29 recipients
Compare payment profiles
Avid Radiopharmaceuticals, Inc.
$1.1M 38 recipients
Compare payment profiles
CONMED Corporation
$1.1M 3,570 recipients
Compare payment profiles
Harrow Eye, LLC
$1.1M 11,566 recipients
Compare payment profiles
Guard Medical SAS
$1.1M 0 recipients
Compare payment profiles
Put this to use
Lumenis BE inc ranks #598 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Lumenis BE inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Lumenis BE inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.